Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 9/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 6/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 5/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HTR1B | P28222 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rauwolscine SCHEMBL12648480 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1ACYP2D6ADRA2CADRA2B | |
| Rauwolscine SCHEMBL4548294 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1ACYP2D6ADRA2CADRA2B | |
| Rauwolscine SCHEMBL8366111 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1ACYP2D6ADRA2CADRA2B | |
| Rauwolscine SCHEMBL7945869 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1ACYP2D6ADRA2CADRA2B | |
| Rauwolscine SCHEMBL25366080 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1ACYP2D6ADRA2CADRA2B | |
| Rauwolscine SCHEMBL6700479 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1ACYP2D6ADRA2CADRA2B | |
| Rauwolscine SCHEMBL23244673 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1ACYP2D6ADRA2CADRA2B | |
| Rauwolscine SCHEMBL564021 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1ACYP2D6ADRA2CADRA2B | |
| Rauwolscine SCHEMBL18541713 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1ACYP2D6ADRA2CADRA2B | |
| Rauwolscine SCHEMBL22703462 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1ACYP2D6ADRA2CADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2141 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250177376-A1 | ALPHA 2 ADRENERGIC RECEPTOR BLOCKADE FOR THE TREATMENT OF C. DIFFICILE COLITIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-06-05 | — | — | US | claimed |
| US-12239641-B2 | Methods of treating or preventing fibrosis in non-alcoholic fatty liver disease | MOOKERJEE RAJESHWAR (GB) | 2025-03-04 | — | — | US | claimed |
| US-20240408090-A1 | Methods Of Treating Dyskinesia And Related Disorders | MELIOR PHARMACEUTICALS II, LLC | 2024-12-12 | — | — | US | claimed |
| US-12048697-B2 | Methods of treating dyskinesia and related disorders | MELIOR PHARMACEUTICALS II, LLC (US) | 2024-07-30 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-11739091-B2 | Process for extracting and purifying Rauwolscine from Rauwolfia plant | Sharma ashok (IN) | 2023-08-29 | — | — | US | claimed |
| WO-2023159253-A2 | ALPHA 2 ADRENERGIC RECEPTOR BLOCKADE FOR THE TREATMENT OF C. DIFFICILE COLITIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2023-08-24 | — | — | WO | claimed |
| US-20230091848-A1 | DISEASE DETECTION AND TREATMENT BASED ON PHENYLACETYL GLUTAMINE LEVELS | THE CLEVELAND CLINIC FOUNDATION | 2023-03-23 | — | — | US | claimed |
| WO-1997027749-A1 | NITROSATED AND NITROSYLATED α-ADRENERGIC RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND THEIR USES | NITROMED, INC. (US) | 1997-08-07 | — | — | WO | claimed |
| US-5635204-A | Method for transdermal induction of anesthesia, analgesia or sedation | MONTEFIORE MEDICAL CENTER (US) | 1997-06-03 | — | — | US | claimed |
| WO-1996004898-A1 | A METHOD OF TREATMENT FOR MALARIA | MCCONNELL BRUCE (US) | 1996-02-22 | — | — | WO | claimed |
| WO-1994008579-A1 | β-AGONIST, α1-AGONIST, AND/OR α2-ANTAGONIST TREATMENT OF NEURODEGENERATIVE DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA | NEW YORK UNIVERSITY (US) | 1994-04-28 | — | — | WO | claimed |
| US-5240930-A | Yohimbine with catecholamine precursor | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1993-08-31 | — | — | US | claimed |
| EP-0120165-B1 | A PREPARATION AND A PROCESS FOR ACHIEVING REGIONAL WEIGHT CONTROL | Greenway III, Frank L. (US) | 1990-07-25 | — | — | EP | claimed |
| US-4659714-A | PROLONGATION WITH VASOCONSTRICTORS; REVERSAL WITH ADRENERGIC BLOCKING AGENTS | DENTSPLY, LTD. (GB) | 1987-04-21 | — | — | US | claimed |
| US-4588724-A | Treatment for selective reduction of regional fat deposits | GREENWAY FRANK L III (US) | 1986-05-13 | — | — | US | claimed |
| EP-0160191-A1 | Kit for treating mammals | Dentsply Limited (GB) | 1985-11-06 | — | — | EP | claimed |
| EP-0120165-A2 | A preparation and a process for achieving regional weight control | Greenway III, Frank L. (US) | 1984-10-03 | — | — | EP | claimed |